The United States and the European Commission have committed to a new Trans-Atlantic Data Privacy Framework, which will foster trans-Atlantic data flows and address the concerns raised by the Court of Justice of the European Union when it struck down in 2020 the Commission’s adequacy decision underlying the EU-U.S. Privacy Shield framework.
This Framework will reestablish an important legal mechanism for transfers of EU personal data to the United States. The United States has committed to implement new safeguards to ensure that signals intelligence activities are necessary and proportionate in the pursuit of defined national security objectives, which will ensure the privacy of EU personal data and to create a new mechanism for EU individuals to seek redress if they believe they are unlawfully targeted by signals intelligence activities. This deal in principle reflects the strength of the enduring U.S.-EU relationship, as we continue to deepen our partnership based on our shared democratic values.
Due to the registration qualifications, there are innovative and generic drugs as well as preparations with the so-called well established use. Companies producing innovative (original) drugs are of great importance in the development of new technologies. However, the pharmaceutical industry in Central and Eastern Europe is dominated by companies producing generic drugs (the so-called generics). Generic drugs are equivalents of original products, the patent protection of which has already expired or has not been applied for. The original and generic medicine may differ in name, manufacturer and price. However, the active substance contained in them, which is responsible for the action of the drug, and its amount will always be the same. Analysts say that the generic drugs market in 2008 was worth EUR 17.2 billion, and predict its further development. Also in Poland, generic companies have a large share in the pharmaceutical sector. Among many European countries, it is Poland that is the leader in terms of value and quantity of generic drugs sold. In terms of value, generic drugs constitute 88% of the drug market in our country, and in quantitative terms – approx. 66%, which is definitely more than in other countries.
On 5-6 April 2022 KIELTYKA GLADKOWSKI participates in Spectral Sessions organized by L3Harris Geospatial. Spectral Sessions is a virtual thought leadership event focused around the trends, benefits and applications of spectral data and analysis. Some of the topics discussed will be:
The Future of Space-Based Data Analysis
Moving Beyond the Light Table: Improving Image Exploitation Tradecraft
Monitoring Methane Point Sources with Commercial and Civil Satellite Imagery Data
New Spectral Technology and Missions
Earth, Wind and Fire: Environmental and Climate-Related Applications for Spectral Data
Widening the Spectral Processing Aperture with ENVI and Open Source Tools
Data fusion is the idea of seamlessly combining different sources of data to provide additional information about an area of interest. This can include data from multiple resolutions of the same modality, or even data from disparate modalities.
KIELTYKA GLADKOWSKI participates in the webinar “The Future of Cybersceurity” organized by techUK and Barclays Corporate Bank, on Thursday, 31 March 2022.
The webinar will be discussing emerging cyber security threats, trends and solutions.
The world of cyber security is constantly evolving, with new technologies, geopolitical events and legislation appearing amidst increased investor and corporate focus. The speakers will analyse the issue of how the cyber security industry is adapting to these changes and ensuring companies stay ahead of potential threats.
KIELTYKA GLADKOWSKI takes part in the event organised jointly by the Observer and Coindesk devoted to DeFi Dozen, taking place on March 29.
The speakers will present and discuss the most trendy DeFi companies of 2022.
The speakers will include James Ledbetter, Executive Editor, Observer; Lisa Carmen Wang, Founder, Bad Bitch Empire and advisor to crypto CEOs; Joe Lautzenhiser, Editorial Researcher and Strategist, CoinDesk.
The event is a great opportunity for KIELTYKA GLADKOWSKI to get the insight into most trendy DeFi companies in the market, since decentralised finance remains crucial specialisation for our law firm, with a particular focus on cryptocurrency exchanges, OTC desks and wallet-providers, DeFi traders and Dapp developers, NFT platforms, issuers, and investors, digital asset platforms, institutional investors and publicly traded companies; cryptocurrency hedge fund managers and investors, metaverse businesses, brands, and users.
